NCT07730567尚未招募1 期
A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B in Healthy Adult Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- 1. Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)
研究概览
简要总结
To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult volunteers aged ≥19 and ≤55 years at the time of the screening visit
- •Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
排除标准
- •Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- •Other exclusions applied
结局指标
主要结局
1. Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)
时间窗: pre-dose (0hour) to 24 hours post-dose
AUCτ,ss
Maximum concentration of drug in plasma at steady state (Cmax,ss)
时间窗: pre-dose (0hour) to 24 hours post-dose
Cmax,ss
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231CHyperlipidemiaHypertensionNCT07312773Addpharma Inc.55
尚未招募
1 期
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322HypertensionNCT07312799Addpharma Inc.41
尚未招募
1 期
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy AdultsChronic Liver Disease (CLD)NCT07521241Addpharma Inc.52
尚未招募
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231CDyslipidemiaHypertensionNCT07590167Addpharma Inc.60
尚未招募
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232Diabetes MellitusNCT07538466Addpharma Inc.50